Recent research reveals that long noncoding RNA (lncRNA) LOC646029 plays a crucial role in suppressing ovarian cancer progression. Scientists discovered that LOC646029 expression drops significantly in metastatic ovarian tumors, which links to a poorer prognosis for patients.
How LOC646029 Inhibits Ovarian Cancer
The study shows LOC646029 acts as a competitive endogenous RNA (ceRNA). It sponges miR-627-3p, a microRNA that can promote cancer cell proliferation and metastasis. By absorbing miR-627-3p, LOC646029 allows the tumor-suppressing gene SPRED1 to function more effectively. This action helps block KRAS signaling, a pathway often linked to tumor growth and metastasis.
Potential as a Prognostic Biomarker
These findings suggest LOC646029 could serve as a valuable prognostic biomarker for ovarian cancer. Higher levels of LOC646029 may indicate better outcomes and a lower risk of metastasis. Researchers believe further studies could pave the way for new diagnostic and therapeutic options targeting the LOC646029/miR-627-3p/SPRED1 axis.
Sources:
Source
